Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISOLDA
2024-514798-23-00Phase 2Completed
- Sponsor
- CR2O
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) and influenza comparing Comirnaty + Fluad Tetra, Comirnaty + Influvac Tetra and Comirnaty + placebo (3 arms). Primary endpoints: Serum neutralizing antibody response to SARS-CoV-2 variants of concern at day 28, Change in geometric mean titres of anti-SARS-CoV-2 spike binding antibodies at day 28 and 1 more. Started Sep 2024; status: completed.
02
Drugs
tozinameraninfluenza virus type B (Victoria)Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on 2024-514798-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514798-23-00.